1. Home
  2. MTVA vs DEVS Comparison

MTVA vs DEVS Comparison

Compare MTVA & DEVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MTVA
  • DEVS
  • Stock Information
  • Founded
  • MTVA 2014
  • DEVS N/A
  • Country
  • MTVA United States
  • DEVS Canada
  • Employees
  • MTVA N/A
  • DEVS N/A
  • Industry
  • MTVA
  • DEVS
  • Sector
  • MTVA
  • DEVS
  • Exchange
  • MTVA NYSE
  • DEVS NYSE
  • Market Cap
  • MTVA 18.9M
  • DEVS 16.5M
  • IPO Year
  • MTVA N/A
  • DEVS N/A
  • Fundamental
  • Price
  • MTVA $1.95
  • DEVS $0.66
  • Analyst Decision
  • MTVA Strong Buy
  • DEVS
  • Analyst Count
  • MTVA 1
  • DEVS 0
  • Target Price
  • MTVA $12.00
  • DEVS N/A
  • AVG Volume (30 Days)
  • MTVA 337.7K
  • DEVS 2.4M
  • Earning Date
  • MTVA 11-07-2024
  • DEVS 02-12-2025
  • Dividend Yield
  • MTVA N/A
  • DEVS N/A
  • EPS Growth
  • MTVA N/A
  • DEVS N/A
  • EPS
  • MTVA N/A
  • DEVS N/A
  • Revenue
  • MTVA N/A
  • DEVS N/A
  • Revenue This Year
  • MTVA N/A
  • DEVS N/A
  • Revenue Next Year
  • MTVA N/A
  • DEVS N/A
  • P/E Ratio
  • MTVA N/A
  • DEVS N/A
  • Revenue Growth
  • MTVA N/A
  • DEVS N/A
  • 52 Week Low
  • MTVA $1.51
  • DEVS $0.48
  • 52 Week High
  • MTVA $6.75
  • DEVS $1.91
  • Technical
  • Relative Strength Index (RSI)
  • MTVA N/A
  • DEVS N/A
  • Support Level
  • MTVA N/A
  • DEVS N/A
  • Resistance Level
  • MTVA N/A
  • DEVS N/A
  • Average True Range (ATR)
  • MTVA 0.00
  • DEVS 0.00
  • MACD
  • MTVA 0.00
  • DEVS 0.00
  • Stochastic Oscillator
  • MTVA 0.00
  • DEVS 0.00

About MTVA METAVIA INC

MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.

About DEVS DEVVSTREAM CORP

DevvStream Corp is a technology based ESG company that advances the development and monetization of environmental assets, with an initial focus on carbon markets. It works with governments and corporations to achieve their sustainability goals through the implementation of curated green technology projects that generate renewable energy, improve energy efficiencies, eliminate or reduce emissions, and sequester carbon directly from the air.

Share on Social Networks: